// App-Quantinova.ai

OA15.03 : Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

Researchers

Presenter

  • A. Spira

Principal Investigators

  • J. Goldman

  • P. Janne

  • C.K. Lee

  • Z. Ma

  • S. Ou

  • R. Salgia

  • Z. Wang

  • G. Gao

  • J. Curtin

  • J.M. Trigo

Medical Centers

  • Mayo Clinic, Rochester, MN

  • Drug Development Unit, The Royal Marsden and Institute of Cancer Research, Sutton, UK

  • Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • David Geffen School of Medcn at UCLA, Los Angeles, CA

  • Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

  • Hospital Universitario Virgen de La Victoria Y Regional, Ibima, Malaga/ES

  • Institut Gustave Roussy, Villejuif,...

  • Virginia Cancer Specialists Research Institute, and Oncology Research, Fairfax, VA

  • St George Hospital, Kogarah/AU

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

  • University of California, Irvine, Orange, CA, USA

  • Janssen R&d, Spring House/PA/US

  • Henan Cancer Hospital, Zhengzhou, China

  • Dana-Farber Cancer Institute, Boston, MA

  • City of Hope, Duarte, CA

Locations

  • United States

  • United Kingdom

  • China

  • Venezuela

  • France

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Expansion Study

  • Dose Escalation

Phase

  • N/A

Study Id's

  • NCT02609776

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved